分子测试对高风险差异化甲状腺癌的结构性复发风险进行分层测试:一项回顾性队列研究
Jie Liu1, Wensi Gao2, Xiong Zheng1
1Department of Head and Neck Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Frontiers in endocrinology
|February 10, 2025
概括
分子检测可以识别高风险的差异化甲状腺癌与与复发相关的遗传改变. 这种方法完善了风险分层,指导个性化的随访和治疗,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子诊断学 分子诊断
背景情况:
- 高风险差异化甲状腺癌 (DTC) 的复发概率更高.
- 2015年美国甲状腺协会风险分层系统 (ATA-RSS) 确定了这些高风险病例.
- 了解分子形状对于提高高风险DTC的预后准确性至关重要.
研究的目的:
- 为了研究高风险DTC的分子特性.
- 评估分子测试在对高风险DTC患者的风险分层改进中的有用性.
- 为了将分子变化与临床结果和复发风险相关联.
主要方法:
- 对108名高风险DTC患者 (2019-2022) 的回顾性分析.
- 使用18基因下一代测序试验进行分子分析.
- 分类为高分子风险 (TERT,TP53,PIK3CA突变) 和非高分子风险组.
主要成果:
- 29.6%的患者属于高分子风险组.
- 高分子风险组显示年龄较大,瘤较大,侵袭性亚型和更远的转移.
- 高分子风险与明显增加的局部复发和远程转移有关.
- 分子分析和瘤大小独立预测了无复发的生存率.
结论:
- 高风险的DTC中晚期受影响的基因变异与复发风险的增加有关.
- 分子测试提供了高风险DTC中复发风险分层的精确方法.
- 个性化后续和治疗策略可以根据分子形状开发.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


